Melissa B. Epperly net worth and biography

Melissa Epperly Biography and Net Worth

Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy cancer company, and prior to that, CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology company. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company focused on international and US based pharmaceutical clients and private equity. She began her career at Morgan Stanley in New York in healthcare investment banking. Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.

What is Melissa B. Epperly's net worth?: The estimated net worth of Melissa B. Epperly is at least $1.57 million as of February 12th, 2024. Ms. Epperly owns 451,449 shares of Zentalis Pharmaceuticals stock worth more than $1,566,528 as of November 17th. This net worth approximation does not reflect any other assets that Ms. Epperly may own. Learn More about Melissa B. Epperly's net worth.
How do I contact Melissa B. Epperly?: The corporate mailing address for Ms. Epperly and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Melissa B. Epperly's contact information.
Has Melissa B. Epperly been buying or selling shares of Zentalis Pharmaceuticals?: Melissa B. Epperly has not been actively trading shares of Zentalis Pharmaceuticals over the course of the past ninety days. Most recently, Melissa B. Epperly sold 2,573 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a transaction totalling $29,435.12. Following the completion of the sale, the chief financial officer now directly owns 451,449 shares of the company's stock, valued at $5,164,576.56. Learn More on Melissa B. Epperly's trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 18,302 shares worth more than $205,276.56. The most recent insider tranaction occured on October, 4th when insider Vincent Vultaggio sold 1,603 shares worth more than $5,097.54. Insiders at Zentalis Pharmaceuticals own 3.6% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 10/4/2024.

Melissa B. Epperly Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/12/2024	Sell	2,573	$11.44	$29,435.12	451,449
10/4/2023	Sell	5,482	$19.50	$106,899.00	387,691
2/13/2023	Sell	2,624	$20.42	$53,582.08	397,275
4/4/2022	Sell	17,080	$50.09	$855,537.20	247,414
2/23/2022	Sell	1,913	$49.10	$93,928.30
8/18/2021	Buy	1,326	$52.00	$68,952.00	258,400
7/1/2021	Sell	3,083	$51.27	$158,065.41	259,457
6/1/2021	Sell	3,083	$54.05	$166,636.15	260,357
5/3/2021	Sell	3,083	$59.24	$182,636.92	265,973
4/5/2021	Sell	17,107	$43.39	$742,272.73	280,347
1/4/2021	Sell	3,083	$51.91	$160,038.53	276,879
12/7/2020	Sell	6,464	$53.52	$345,953.28	288,020
12/4/2020	Sell	7,220	$50.98	$368,075.60	288,020
12/2/2020	Sell	3,083	$51.47	$158,682.01	293,746
11/23/2020	Sell	3,083	$46.58	$143,606.14	297,529
4/7/2020	Buy	20,000	$18.00	$360,000.00	297,529

Melissa B. Epperly Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $3.47

$3.36

$4.00

50 Day Range

MA: $3.42

$2.70

$4.36

2 Week Range

Now: $3.47

$2.66

$18.07

Volume

1,832,087 shs

Average Volume

1,566,191 shs

Market Capitalization

$247.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.